Skip to main content

OrbiMed Capital LLC

No open-market purchases or sales filed in the past year.

Current role at each company

Show 3 more companies

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
–
0 filings
Net
–
Bought minus sold
Companies
0
With open-market trades

Trades

Every Form 4 that lists OrbiMed Capital LLC as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

PRLD Prelude Therapeutics Inc

Director, 10% Owner2 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 23, 2026 (view filing)6:48 PM ETApr 212 daysOrbiMed Advisors LLC and 3 othersDirector, 10% OwnerPPurchase+2.82M$4.44+$12.5MNew position1.13M after2 lotsDuplicate filing
May 24, 2023 (view filing)5:09 PM ETMay 222 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+869.6K$5.75+$5.00M+9.4%10.1M afterDuplicate filing

SPRY ARS Pharmaceuticals, Inc.

Director3 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 28, 2024 (view filing)4:26 PM ETAug 262 daysOrbiMed Advisors LLC and 2 othersDirectorSSale−83.7K$13.00−$1.09M−100.0%0 afterDuplicate filing
Aug 23, 2024 (view filing)6:38 PM ETAug 21-232 daysOrbiMed Advisors LLC and 2 othersDirectorSSale−868.7K$13.24−$11.5M−91.2%83.7K after4 lotsDuplicate filing
Aug 31, 2023 (view filing)5:26 PM ETAug 292 daysOrbiMed Advisors LLC and 2 othersDirectorPPurchase+500.0K$6.20+$3.10M+6.6%8.02M afterDuplicate filing

KNTE Kinnate Biopharma Inc.

Director, 10% Owner3 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 8, 2023 (view filing)5:22 PM ETMay 4-54 daysOrbiMed Advisors LLC and 6 othersDirector, 10% OwnerPPurchase+1.46M$2.80+$4.09MNew position1.37M after5 lotsDuplicate filing
May 2, 2023 (view filing)9:34 PM ETApr 28-May 24 daysOrbiMed Advisors LLC and 6 othersDirector, 10% OwnerPPurchase+1.41M$2.61+$3.67MNew position794.4K after9 lotsDuplicate filing
Feb 15, 2022 (view filing)9:42 PM ETFeb 11-154 daysOrbiMed Advisors LLC and 3 othersDirectorPPurchase+195.7K$10.17+$1.99M+5.9%3.51M after4 lotsDuplicate filing

ARQT Arcutis Biotherapeutics, Inc.

10% Owner2 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 28, 2022 (view filing)4:29 PM ETJun 244 daysOrbiMed Advisors LLC and 2 others10% OwnerSSale−342.0K$21.31−$7.29M−45.2%415.1K after2 lots
Apr 8, 2022 (view filing)6:06 PM ETApr 6-82 daysOrbiMed Advisors LLC and 2 others10% OwnerSSale−878.2K$20.68−$18.2M−66.1%451.1K after6 lots

PMVP PMV Pharmaceuticals, Inc.

10% Owner1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 31, 2022 (view filing)5:30 PM ETMar 29-312 daysOrbiMed Advisors LLC and 3 others10% OwnerSSale−474.5K$21.63−$10.3M−100.0%0 after3 lots

RPTX Repare Therapeutics Inc.

Director5 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 8, 2021 (view filing)6:18 PM ETSep 3-75 daysOrbiMed Advisors LLC and 2 othersDirectorSSale−8.08K$33.99−$274.8K−7.8%96.2K after4 lotsDuplicate filing
Sep 2, 2021 (view filing)8:27 PM ETAug 31-Sep 22 daysOrbiMed Advisors LLC and 2 othersDirectorSSale−37.9K$34.08−$1.29M−28.2%96.4K after6 lotsDuplicate filing
Aug 30, 2021 (view filing)6:37 PM ETAug 26-304 daysOrbiMed Advisors LLC and 2 othersDirectorSSale−18.1K$34.07−$615.7K−15.6%97.5K after6 lotsDuplicate filing
Aug 25, 2021 (view filing)8:43 PM ETAug 23-252 daysOrbiMed Advisors LLC and 2 othersDirectorSSale−18.2K$34.17−$622.4K−15.7%98.1K after6 lotsDuplicate filing
Aug 19, 2021 (view filing)8:55 PM ETAug 17-182 daysOrbiMed Advisors LLC and 2 othersDirectorSSale−20.3K$34.10−$693.2K−17.1%98.6K after4 lotsDuplicate filing

ELVN Enliven Therapeutics, Inc.

Director, 10% Owner1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 16, 2021 (view filing)4:27 PM ETJul 16Same dayOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+1.67M$6.00+$10.0MNew position1.67M after